WO2005123081A3 - (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia - Google Patents

(2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia Download PDF

Info

Publication number
WO2005123081A3
WO2005123081A3 PCT/EP2005/052887 EP2005052887W WO2005123081A3 WO 2005123081 A3 WO2005123081 A3 WO 2005123081A3 EP 2005052887 W EP2005052887 W EP 2005052887W WO 2005123081 A3 WO2005123081 A3 WO 2005123081A3
Authority
WO
WIPO (PCT)
Prior art keywords
methanone
piperazin
schizophrenia
pyrrolidin
piperidin
Prior art date
Application number
PCT/EP2005/052887
Other languages
French (fr)
Other versions
WO2005123081A2 (en
Inventor
Anne Simone Josephine Lesage
David Ashton
Frans Eduard Janssens
Original Assignee
Janssen Pharmaceutica Nv
Anne Simone Josephine Lesage
David Ashton
Frans Eduard Janssens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Anne Simone Josephine Lesage, David Ashton, Frans Eduard Janssens filed Critical Janssen Pharmaceutica Nv
Publication of WO2005123081A2 publication Critical patent/WO2005123081A2/en
Publication of WO2005123081A3 publication Critical patent/WO2005123081A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)

Abstract

This invention concerns the use of 2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)­pyrrolidin-3-yl]-piperazin- l -yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl)-methanone and its derivatives having neurokinin antagonistic activity, in particular a combined NK1/NK2/NK3 antagonistic activity and to modulate the activity of dopaminergic pathways in the brain, as a medicine for the prophylactic and/or therapeutic treatment of schizophrenia. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof.
PCT/EP2005/052887 2004-06-22 2005-06-21 (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia WO2005123081A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102885 2004-06-22
EP04102885.3 2004-06-22

Publications (2)

Publication Number Publication Date
WO2005123081A2 WO2005123081A2 (en) 2005-12-29
WO2005123081A3 true WO2005123081A3 (en) 2006-03-16

Family

ID=34979589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/052887 WO2005123081A2 (en) 2004-06-22 2005-06-21 (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia

Country Status (1)

Country Link
WO (1) WO2005123081A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
AU2013254674B2 (en) 2012-04-27 2017-02-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016440A1 (en) * 1995-10-30 1997-05-09 Janssen Pharmaceutica N.V. 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
WO2004033428A1 (en) * 2002-10-08 2004-04-22 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004056799A2 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016440A1 (en) * 1995-10-30 1997-05-09 Janssen Pharmaceutica N.V. 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
WO2004033428A1 (en) * 2002-10-08 2004-04-22 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004056799A2 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
WO2005123081A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
NO331174B1 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
PL377285A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
TW200502230A (en) Dual nk1/nk3 derivatives
TWI255807B (en) Therapeutic agents
SG154443A1 (en) Piperidine derivatives as nk1 antagonists
AU2003281213A1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
TW200602339A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
MX2007000505A (en) Substituted oxindol derivatives and medicaments containing the same.
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
IL166413A0 (en) Use of and some novel imidazopyridines
MXPA05006420A (en) Pyrimidine derivates for the treatment of abnormal cell growth.
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MY135841A (en) Novel benzodioxoles
IL184125A (en) Use of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)- methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6 methoxycarbonyl-2-indolinone for the preparation of a medicaments for the prevention or treatment of idiopathic pulmonary fibrosis
RS20050199A (en) Imidazolopyridines and methods of making and using the same
CA2603830A1 (en) Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
MXPA05012415A (en) Isoquinoline derivatives and their use as gfat inhibitors.
IL166412A0 (en) Novel use of benzothiazole derivatives
HK1074046A1 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
MXPA04000278A (en) Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury.
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
NO20052182L (en) New connections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase